Ilija Andrijevic1, Senka Milutinov1, Zagorka Lozanov Crvenkovic2, Jovan Matijasevic1, Ana Andrijevic1, Tomi Kovacevic1, Darijo Bokan1, Bojan Zaric3. 1. Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Put doktora Goldmana 4, 21204, Sremska Kamenica, Serbia. 2. Faculty of Sciences, University of Novi Sad, Sremska Kamenica, Serbia. 3. Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Put doktora Goldmana 4, 21204, Sremska Kamenica, Serbia. bojan.zaric@institut.rs.
Abstract
INTRODUCTION: Left ventricular systolic dysfunction (LVSD) and cardiac decompensation often accompany AECOPD. Differentiation between the two is difficult and mainly relies on clinical and echocardiographic diagnostic procedures. The value of biomarkers, such as NT-proBNP, as diagnostic tools is still insufficiently investigated. The main goals of this trial were to investigate the value of NT-proBNP as a diagnostic tool for LVSD in AECOPD patients and determine its cut-off value which could reliably diagnose LVSD during AECOPD. PATIENTS AND METHODS: This trial prospectively enrolled 209 patients with AECOPD. The patients were divided into four groups-AECOPD plus chronic pulmonary heart disease (CPHD) with or without left ventricular compromise (LVSD), and AECOPD patients without CPHD with or without LVSD. NT-proBNP was measured within first 48 h of hospitalization. RESULTS:Majority of patients were male (61%) active smokers (41.6%), average age of 68 years. High quality of echocardiography was obtained in 63.3 and 22.5% of the patients had LVSD. Average value of NT-proBNP in patients with LVSD was 3303.2 vs. 1092.5 pg/mL in patients without LVSD. Significant differences in NT-proBNP value (p = 0.0001) were determined between observed patient groups. At the cut-off value of 1505 pg/mL, sensitivity, specificity, and positive and negative predictive values are 76.6, 83.3, 57.1, and 92.47%, respectively. CONCLUSION: At the cut-off value of 1505 pg/mL NT-proBNP could be used as a diagnostic marker for LVSD in acute exacerbation of COPD.
RCT Entities:
INTRODUCTION:Left ventricular systolic dysfunction (LVSD) and cardiac decompensation often accompany AECOPD. Differentiation between the two is difficult and mainly relies on clinical and echocardiographic diagnostic procedures. The value of biomarkers, such as NT-proBNP, as diagnostic tools is still insufficiently investigated. The main goals of this trial were to investigate the value of NT-proBNP as a diagnostic tool for LVSD in AECOPD patients and determine its cut-off value which could reliably diagnose LVSD during AECOPD. PATIENTS AND METHODS: This trial prospectively enrolled 209 patients with AECOPD. The patients were divided into four groups-AECOPD plus chronic pulmonary heart disease (CPHD) with or without left ventricular compromise (LVSD), and AECOPD patients without CPHD with or without LVSD. NT-proBNP was measured within first 48 h of hospitalization. RESULTS: Majority of patients were male (61%) active smokers (41.6%), average age of 68 years. High quality of echocardiography was obtained in 63.3 and 22.5% of the patients had LVSD. Average value of NT-proBNP in patients with LVSD was 3303.2 vs. 1092.5 pg/mL in patients without LVSD. Significant differences in NT-proBNP value (p = 0.0001) were determined between observed patient groups. At the cut-off value of 1505 pg/mL, sensitivity, specificity, and positive and negative predictive values are 76.6, 83.3, 57.1, and 92.47%, respectively. CONCLUSION: At the cut-off value of 1505 pg/mL NT-proBNP could be used as a diagnostic marker for LVSD in acute exacerbation of COPD.
Authors: Roderick H Tung; Carlos A Camargo; Dan Krauser; Saif Anwaruddin; Aaron Baggish; Annabel Chen; James L Januzzi Journal: Ann Emerg Med Date: 2006-02-17 Impact factor: 5.721
Authors: Robert Marcun; Ivan Stankovic; Radosav Vidakovic; Jerneja Farkas; Sasa Kadivec; Biljana Putnikovic; Ivan Ilic; Aleksandar N Neskovic; Mitja Lainscak Journal: Intern Emerg Med Date: 2015-09-30 Impact factor: 3.397
Authors: Araceli Molina Medina; Marta Sanchez Marteles; Elisa Bermejo Sáiz; Sandra Serrano Martínez; Fernando Ruiz Laiglesia; José A Nieto Rodríguez; Juan I Pérez-Calvo Journal: Eur J Intern Med Date: 2011-01-05 Impact factor: 4.487
Authors: Frans H Rutten; Maarten-Jan M Cramer; Nicolaas P A Zuithoff; Jan-Willem J Lammers; Wim Verweij; Diederick E Grobbee; Arno W Hoes Journal: Eur J Heart Fail Date: 2007-03-07 Impact factor: 15.534
Authors: Anant R C Patel; Beverly S Kowlessar; Gavin C Donaldson; Alex J Mackay; Richa Singh; Siobhan N George; Davinder S Garcha; Jadwiga A Wedzicha; John R Hurst Journal: Am J Respir Crit Care Med Date: 2013-11-01 Impact factor: 21.405